<DOC>
	<DOCNO>NCT00497731</DOCNO>
	<brief_summary>The primary purpose protocol investigate safety tolerability AZD1152 give continuous 2-hour infusion every week every 2 week patient advance solid malignancy .</brief_summary>
	<brief_title>AZD1152 Patients With Advanced Solid Malignancies-Study 1</brief_title>
	<detailed_description />
	<criteria>Histological cytological confirmation solid , malignant tumour At least measurable non measurable site disease define modified RECIST criterion . Participation investigational drug study within 30 day prior entry recovered effect investigational study drug Treatment radiotherapy/chemotherapy 4 week first dose Recent major surgery within 4 week prior entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Advanced solid tumor</keyword>
</DOC>